Abstract
Approximately 11% of monogenic diseases involve nonsense mutations that are caused by premature termination codons. These codons can in principle be read-through via the site-specific incorporation of unnatural amino acids to generate full-length proteins with minimal loss of function. Here we report that aminoacyl-tRNA-synthase–tRNA pairs specific for the desired unnatural amino acids can be used to read through a nonsense mutation in the dystrophin gene. We show partial restoration of dystrophin expression in differentiated primary myoblasts (from a mdx mouse model and a patient with Duchenne muscular dystrophy), and restoration of muscle function in two mouse models: mdx mice, via viral delivery of the engineered tRNA-synthase–tRNA pair intraperitoneally or intramuscularly and of the associated unnatural amino acid intraperitoneally; and mice produced by crossing mdx mice and transgenic mice with a chromosomally integrated pair, via intraperitoneal delivery of the unnatural amino acid. The incorporation of unnatural amino acids to restore endogenous protein expression could be explored for therapeutic use.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The main data supporting the findings of this study are available within this paper and its Supplementary Information. Transcriptomics data of different mouse tissues are available in the Gene Expression Omnibus (GEO) repository, with accession code GSE158961. The UAA incorporation sites were based on reported DMD cases from the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php). Source data are provided with this paper.
References
Chin, J. W. Expanding and reprogramming the genetic code of cells and animals. Annu. Rev. Biochem. 83, 379–408 (2014).
Davis, L. & Chin, J. W. Designer proteins: applications of genetic code expansion in cell biology. Nat. Rev. Mol. Cell Biol. 13, 168–182 (2012).
Zheng, Y. N. et al. Expanding the scope of single- and double-noncanonical amino acid mutagenesis in mammalian cells using orthogonal polyspecific leucyl-tRNA synthetases. Biochemistry 57, 441–445 (2018).
Young, D. D. & Schultz, P. G. Playing with the molecules of life. ACS Chem. Biol. 13, 854–870 (2018).
Wang, Q., Parrish, A. R. & Wang, L. Expanding the genetic code for biological studies. Chem. Biol. 16, 323–336 (2009).
Sachdeva, A., Wang, K., Elliott, T. & Chin, J. W. Concerted, rapid, quantitative, and site-specific dual labeling of proteins. J. Am. Chem. Soc. 136, 7785–7788 (2014).
Schmied, W. H., Elsasser, S. J., Uttamapinant, C. & Chin, J. W. Efficient multisite unnatural amino acid incorporation in mammalian cells via optimized pyrrolysyl tRNA synthetase/tRNA expression and engineered eRF1. J. Am. Chem. Soc. 136, 15577–15583 (2014).
Wan, W., Tharp, J. M. & Liu, W. R. Pyrrolysyl-tRNA synthetase: an ordinary enzyme but an outstanding genetic code expansion tool. Biochim. Biophys. Acta 1844, 1059–1070 (2014).
Nozawa, K. et al. Pyrrolysyl-tRNA synthetase-tRNA(Pyl) structure reveals the molecular basis of orthogonality. Nature 457, 1163–1167 (2009).
Bladen, C. L. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395–402 (2015).
Fujikura, K. Premature termination codons in modern human genomes. Sci. Rep. 6, 22468 (2016).
Bidou, L., Allamand, V., Rousset, J. P. & Namy, O. Sense from nonsense: therapies for premature stop codon diseases. Trends Mol. Med. 18, 679–688 (2012).
Hilton-Jones, D. & Squier, M. V. Dystrophin-associated protein complex: clinical implications. Lancet 341, 528–529 (1993).
Hoffman, E. P., Brown, R. H. Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987).
Hug, N., Longman, D. & Caceres, J. F. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res. 44, 1483–1495 (2016).
Godfrey, C. et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum. Mol. Genet. 24, 4225–4237 (2015).
Oude Blenke, E., Evers, M. J., Mastrobattista, E. & van der Oost, J. CRISPR-Cas9 gene editing: delivery aspects and therapeutic potential. J. Control. Release 244, 139–148 (2016).
Karijolich, J. & Yu, Y. T. Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (review). Int. J. Mol. Med. 34, 355–362 (2014).
Antonarakis, S. E. & Cooper, D. N. Emery and Rimoin’s Principles and Practice of Medical Genetics Ch. 7.4.15 (Academic Press, 2013).
Asiful Islam, M. et al. Therapeutic suppression of nonsense mutation: an emerging target in multiple diseases and thrombotic disorders. Curr. Pharm. Des. 23, 1598–1609 (2017).
Bostick, B., Shin, J. H., Yue, Y. & Duan, D. AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol. Ther. 19, 1826–1832 (2011).
Brolin, C. & Shiraishi, T. Antisense mediated exon skipping therapy for Duchenne muscular dystrophy (DMD). Artif. DNA PNA XNA 2, 6–15 (2011).
Long, C. et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345, 1184–1188 (2014).
Han, S. et al. Expanding the genetic code of Mus musculus. Nat. Commun. 8, 14568 (2017).
Chin, J. W., Cropp, T. A., Chu, S., Meggers, E. & Schultz, P. G. Progress toward an expanded eukaryotic genetic code. Chem. Biol. 10, 511–519 (2003).
Suzuki, T. et al. Crystal structures reveal an elusive functional domain of pyrrolysyl-tRNA synthetase. Nat. Chem. Biol. 13, 1261–1266 (2017).
Wang, L. Engineering the genetic code in cells and animals: biological considerations and impacts. Acc. Chem. Res. 50, 2767–2775 (2017).
Tadayoni, R., Rendon, A., Soria-Jasso, L. E. & Cisneros, B. Dystrophin Dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene. Mol. Neurobiol. 45, 43–60 (2012).
Nishida, A. et al. HEK293 cells express dystrophin Dp71 with nucleus-specific localization of Dp71ab. Histochem. Cell Biol. 146, 301–309 (2016).
Liu, L., Cheung, T. H., Charville, G. W. & Rando, T. A. Isolation of skeletal muscle stem cells by fluorescence-activated cell sorting. Nat. Protoc. 10, 1612–1624 (2015).
Latroche, C., Weiss-Gayet, M., Gitiaux, C. & Chazaud, B. Cell sorting of various cell types from mouse and human skeletal muscle. Methods 134–135, 50–55 (2018).
Barberi, T. et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat. Med. 13, 642–648 (2007).
Garcia, S. M., Tamaki, S., Xu, X. & Pomerantz, J. H. Human satellite cell isolation and xenotransplantation. Methods Mol. Biol. 1668, 105–123 (2017).
Zhu, P. et al. CRISPR/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy. Mol. Ther. Nucleic Acids 7, 31–41 (2017).
Brown, W., Liu, J. & Deiters, A. Genetic code expansion in animals. ACS Chem. Biol. 13, 2375–2386 (2018).
Chatterjee, A., Guo, J. T., Lee, H. S. & Schultz, P. G. A genetically encoded fluorescent probe in mammalian cells. J. Am. Chem. Soc. 135, 12540–12543 (2013).
Chatterjee, A., Sun, S. B., Furman, J. L., Xiao, H. & Schultz, P. G. A versatile platform for single- and multiple-unnatural amino acid mutagenesis in Escherichia coli. Biochemistry 52, 1828–1837 (2013).
Elliott, T. S. et al. Proteome labeling and protein identification in specific tissues and at specific developmental stages in an animal. Nat. Biotechnol. 32, 465–472 (2014).
Lajoie, M. J., Soll, D. & Church, G. M. Overcoming challenges in engineering the genetic code. J. Mol. Biol. 428, 1004–1021 (2016).
Swart, E. C., Serra, V., Petroni, G. & Nowacki, M. Genetic codes with no dedicated stop codon: context-dependent translation termination. Cell 166, 691–702 (2016).
Keeling, K. M. & Bedwell, D. M. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. WIREs RNA 2, 837–852 (2011).
Le Guiner, C. et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat. Commun. 8, 16105 (2017).
Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67, 771–780 (2010).
Krogager, T. P. et al. Labeling and identifying cell-specific proteomes in the mouse brain. Nat. Biotechnol. 36, 156–159 (2018).
Duan, D. & Systemic, A. A. V. micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337–2356 (2018).
Lim, K. R. Q., Yoon, C. & Yokota, T. Applications of CRISPR/Cas9 for the treatment of Duchenne muscular dystrophy. J. Pers. Med. 8, 38 (2018).
Bossi, L. & Roth, J. R. The influence of codon context on genetic code translation. Nature 286, 123–127 (1980).
Knight, R. D., Freeland, S. J. & Landweber, L. F. Rewiring the keyboard: evolvability of the genetic code. Nat. Rev. Genet. 2, 49–58 (2001).
Nguyen, D. et al. Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolysyl-tRNA synthetase/tRNACUA pair and click chemistry. J. Am. Chem. Soc. 131, 8720–8721 (2009).
Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S. & Blau, H. M. Self-renewal and expansion of single transplanted muscle stem cells. Nature 456, 502–506 (2008).
Cossarizza, A. et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur. J. Immunol. 49, 1457–1973 (2019).
Liang, J. et al. Low-dose tubacin promotes BMSCs proliferation and morphological changes through the ERK pathway. Am. J. Transl. Res. 11, 1446–1459 (2019).
Corchete, L. et al. Systematic comparison and assessment of RNA‑seq procedures for gene expression quantitative analysis. Sci. Rep. 10, 19737 (2020).
Acknowledgements
This work was supported by the National Science and Technology Major Projects for Major New Drugs Innovation and Development (grant numbers 2018ZX09711003-001-003 and 2018ZX09J18114) of China.
Author information
Authors and Affiliations
Contributions
Q.Y. and Q.X. conceived the idea and designed the experiments. Q.Y. and N.S. performed the experiments and offered the original images. H.Z. and N.S. organized the results, analysed the data, prepared the figures and wrote the manuscript. H.L. and X.Y. edited the manuscript and gave technical advice. All other authors participated in some of the experiments, results or discussion. Q.X. supervised the study.
Corresponding author
Ethics declarations
Competing interests
Q.Y. and Q.X. are listed as co-inventors on patents regarding the PylRS–tRNA system for dystrophin read-through and DMD therapy (PCT/CN2017/075577 and CN 2016/10134657.6). The other authors declare no competing interests.
Additional information
Peer review information Nature Biomedical Engineering thanks the anonymous reviewers for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary figures, tables and nucleic acid sequences.
Supplementary Data
Source data for Supplementary Figs. 5, 6, 10, 11, 17 and 18.
Source data
Source Data for Fig. 3
Source data.
Source Data for Fig. 4
Source data.
Source Data for Fig. 5
Source data.
Source Data for Fig. 6
Source data.
Rights and permissions
About this article
Cite this article
Shi, N., Yang, Q., Zhang, H. et al. Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids. Nat Biomed Eng 6, 195–206 (2022). https://doi.org/10.1038/s41551-021-00774-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-021-00774-1
This article is cited by
-
Combining nucleotide variations and structure variations for improving astaxanthin biosynthesis
Microbial Cell Factories (2022)